Free Newsletter
M&A menu: India's top 10 drugmakers
Free newsletter via e-mail
Tools
SPOTLIGHT: India's top 10 drugmakers
As soon as Ranbaxy's founding Singh family agreed to sell out to Japan's Daiichi Sankyo, the Indian press started speculating about which pharma firm might be next on the buyout list. Well, we can't pretend any knowledge of upcoming M&As, but we can point you to a ranking of subcontinental drugmakers--by revenue--for your own speculative pleasure. Changes are the next target would be among this top 10. Report
Comments
By Pharma man | Posted 11:32am | June 21, 2008
Sales viewed in isolation do not mean much in the Pharma world.
One Indian company stands out in the generic space -- That is Sun Pharmaceuticals. Sanghvi knows the business inside out and is as shrewd a manager as there is.
One Indian company stands out in the R&D space -- and that is Glenmark which is not even part of the top 10 list. Glen knows how to approach R&D better than any of the entrepreneurs in this space -- and certainly better than the Malvinder's of the world.
Malvinder made a good move to sell out -- he is not a pharma man, only an inheritor of the mantel, and not a worthy one at that. If he knew the business and could build it, he would not have sold out. Parminder would hang his head in shame if he knew what his son had done. One of India's jewels is gone.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
